Yongkun Yang1, Xiaohui Niu2, Yuan Li1, Weifeng Liu1, Hairong Xu1. 1. Department of Orthopedic Oncology, Beijing Ji Shui Tan Hospital, Peking University, Beijing, People's Republic of China. 2. Department of Orthopedic Oncology, Beijing Ji Shui Tan Hospital, Peking University, Beijing, People's Republic of China. niuxiaohui@263.net.
Abstract
PURPOSE: To evaluate postoperative recurrence, survival and metastasis results and related factors of sacral chordoma. METHODS: Between 1978 and 2013, a total of 171 patients with sacral chordoma were diagnosed at our institution and 162 cases underwent operation. The clinical characteristics, treatment and outcomes of all these patients were reviewed. RESULTS: The 3-year recurrence free survival rate was 83.1%. The median recurrence free survival time was 73 ± 7.8 months. Tumor level in sacrum and surgical margin were significant factors influencing recurrence. Recurrence was significant factor influencing metastasis. One hundred and fifty-seven cases were followed up for an average of 55.6 months. 135 cases (86%) survived, 37 cases (23.6%) developed recurrence, and 17 cases (10.8%) developed metastasis. The overall 5- and 10-year survival rate was 88.3% and 59.6%, respectively. Age (p = 0.037) and metastasis (p = 0.001) were significant factors influencing survival. The 3-year recurrence free survival rate was 80.1%. The median recurrence free survival time was 69 ± 12.7 months. Tumor level in sacrum (p = 0.035) and surgical margin (p = 0.009) were significant factors influencing recurrence. Seventeen cases (10.8%) had metastasis. Recurrence (p = 0.016) was significant factors influencing metastasis. CONCLUSIONS: Sacral chordoma tended to occur in elderly male patients and locate below sacral 3 level. The recurrence rate was high, especially for tumor above sacral 3 level. Wide surgical margin is very important for good local control. The patients with metastasis had poor prognosis.
PURPOSE: To evaluate postoperative recurrence, survival and metastasis results and related factors of sacral chordoma. METHODS: Between 1978 and 2013, a total of 171 patients with sacral chordoma were diagnosed at our institution and 162 cases underwent operation. The clinical characteristics, treatment and outcomes of all these patients were reviewed. RESULTS: The 3-year recurrence free survival rate was 83.1%. The median recurrence free survival time was 73 ± 7.8 months. Tumor level in sacrum and surgical margin were significant factors influencing recurrence. Recurrence was significant factor influencing metastasis. One hundred and fifty-seven cases were followed up for an average of 55.6 months. 135 cases (86%) survived, 37 cases (23.6%) developed recurrence, and 17 cases (10.8%) developed metastasis. The overall 5- and 10-year survival rate was 88.3% and 59.6%, respectively. Age (p = 0.037) and metastasis (p = 0.001) were significant factors influencing survival. The 3-year recurrence free survival rate was 80.1%. The median recurrence free survival time was 69 ± 12.7 months. Tumor level in sacrum (p = 0.035) and surgical margin (p = 0.009) were significant factors influencing recurrence. Seventeen cases (10.8%) had metastasis. Recurrence (p = 0.016) was significant factors influencing metastasis. CONCLUSIONS:Sacral chordoma tended to occur in elderly male patients and locate below sacral 3 level. The recurrence rate was high, especially for tumor above sacral 3 level. Wide surgical margin is very important for good local control. The patients with metastasis had poor prognosis.
Authors: Christopher A Hulen; H Thomas Temple; William P Fox; Andrew A Sama; Barth A Green; Frank J Eismont Journal: J Bone Joint Surg Am Date: 2006-07 Impact factor: 5.284
Authors: Bruno Fuchs; Ian D Dickey; Michael J Yaszemski; Carrie Y Inwards; Franklin H Sim Journal: J Bone Joint Surg Am Date: 2005-10 Impact factor: 5.284
Authors: Thomas F DeLaney; Norbert J Liebsch; Frank X Pedlow; Judith Adams; Elizabeth A Weyman; Beow Y Yeap; Nicolas Depauw; G Petur Nielsen; David C Harmon; Sam S Yoon; Yen-Lin Chen; Joseph H Schwab; Francis J Hornicek Journal: J Surg Oncol Date: 2014-04-19 Impact factor: 3.454
Authors: Cao Yang; Francis J Hornicek; Kirkham B Wood; Joseph H Schwab; Edwin Choy; Henry Mankin; Zhenfeng Duan Journal: Spine (Phila Pa 1976) Date: 2010-08-15 Impact factor: 3.468
Authors: Madhurima R Chetan; Paul C Lyon; Feng Wu; Rachel Phillips; David Cranston; Martin J Gillies; Stana Bojanic Journal: Radiol Case Rep Date: 2019-08-01